FibroGen, Inc. — Q1 2017 Form 10-Q
Entity note: The supplied filing is for FibroGen, Inc., not Kyntra Bio, Inc. It covers the quarter ended March 31, 2017; the financial statements are unaudited.
Business context and reporting period
FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia associated with chronic kidney disease (CKD); pamrevlumab was in Phase 2 development for idiopathic pulmonary fibrosis, pancreatic cancer, Duchenne muscular dystrophy, and other conditions. Revenue primarily came from Astellas and AstraZeneca collaboration agreements; the company had no approved products or product-sale revenue.
Key financial metrics
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Total revenue | $26.9 million | $28.3 million; down 5% |
| Operating expenses | $58.3 million | $55.1 million; up 6% |
| Loss from operations | $31.4 million | $26.8 million |
| Net loss | $33.2 million | $27.8 million |
| Net loss per share, basic and diluted | $0.52 | $0.45 |
| Operating loss as a share of revenue | Approximately 117% | Approximately 95% |
| Cash used in operating activities | $27.1 million | $17.3 million |
| Cash and cash equivalents | $170.6 million | $173.8 million at December 31, 2016 |
| Short- and long-term investments | $126.0 million | $150.4 million at December 31, 2016 |
| Total liabilities | $290.8 million | $294.4 million at December 31, 2016 |
Cash, investments, and accounts receivable totaled $303.8 million at quarter-end. Long-term lease financing obligations were $97.5 million, and product development obligations were $15.2 million. The filing does not report a conventional borrowing balance. Gross margin is not presented. At March 31, cash and investments totaled approximately $296.6 million; the company subsequently reported $115.1 million of net proceeds from an April follow-on offering.
Material changes versus the prior comparable period
- Revenue fell $1.4 million, principally because the estimated AstraZeneca joint development service period was extended from the end of 2018 to the end of 2020, spreading revenue recognition over a longer period. Higher reimbursable co-development costs partly offset this effect.
- Research and development expense rose $3.1 million, including increased pamrevlumab drug-substance manufacturing and roxadustat Phase 3 trial costs. General and administrative expense was broadly unchanged.
- Net loss widened by approximately $5.3 million. Operating cash use increased by approximately $9.9 million.
- Cash and investments declined by $27.8 million from year-end, while cash and cash equivalents alone decreased by $3.2 million. Investing cash inflows primarily reflected sales and maturities of securities, not operating performance.
Outlook, commentary, and risks
- Management expected to file a U.S. roxadustat NDA in 2018. It expected to complete the 52-week safety exposure portion of the China CKD studies in Q2 2017 and submit a China NDA in Q3 2017.
- For roxadustat in myelodysplastic syndromes, FibroGen planned to initiate a U.S. Phase 3 study in Q3 2017 and a China Phase 2/3 study in Q4 2017.
- Topline results from the placebo-controlled portion of the pamrevlumab IPF Phase 2 trial were expected in Q3 2017. Pancreatic cancer trial enrollment was expected to finish in Q2 2017, with surgical assessment data anticipated in Q4 2017 or Q1 2018.
- Management expected continuing losses and increasing research and development spending, but stated existing cash, investments, and receivables were expected to fund anticipated cash requirements for at least 12 months. This estimate is subject to execution, spending, and financing risks.
- Roxadustat’s development and commercialization depend substantially on Astellas and AstraZeneca, and results, regulatory review, safety, trial execution, manufacturing, reimbursement, competition, and partner decisions could materially affect prospects. The company also highlighted significant China regulatory, manufacturing, operational, and intellectual-property risks.
- The company planned to adopt the new revenue standard in Q1 2018 using full retrospective application. It said milestone amounts recognized under the existing approach would be treated as arrangement consideration and could be deferred under the new standard; the final impact remained under evaluation.
- An April 11, 2017 follow-on offering sold 5,228,750 shares at $22.95 per share. The resulting capital strengthens liquidity but dilutes existing shareholders.
Important facts for investors to verify
- Confirm the issuer identity: this filing is FibroGen, Inc., not Kyntra Bio, Inc.
- Track roxadustat trial progress, safety outcomes, regulatory milestones, and whether the stated U.S. and China submission timelines were achieved.
- Monitor pamrevlumab trial readouts and spending, particularly because these programs are not described as funded by a collaboration partner.
- Assess operating cash burn and liquidity after the April offering, including how proceeds are deployed and the effect of ongoing dilution.
- Review future revenue recognition disclosures for the impact of adopting the new revenue standard and the extended AstraZeneca development period.
- Evaluate reliance on Astellas and AstraZeneca, lease and development obligations, and the risks to trial supply, manufacturing, reimbursement, and commercialization.